|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Protein C measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study.
|
20802025 |
2010 |
|
Protein C antigen measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study.
|
20802025 |
2010 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.
|
23270540 |
2012 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
All class IA p110 subunits interact with p85 regulatory subunits, and mutations/deletions in different p85 regulatory subunits have been identified in both cancer and primary immunodeficiencies.
|
29616047 |
2018 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Mutation or loss of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) is emerging as a transforming factor in cancer, but the mechanism of transformation has been controversial.
|
28630349 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.
|
23270540 |
2012 |
|
Primary malignant neoplasm
|
0.080 |
GeneticVariation
|
group |
BEFREE |
All class IA p110 subunits interact with p85 regulatory subunits, and mutations/deletions in different p85 regulatory subunits have been identified in both cancer and primary immunodeficiencies.
|
29616047 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Mutation or loss of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) is emerging as a transforming factor in cancer, but the mechanism of transformation has been controversial.
|
28630349 |
2017 |
|
Carcinogenesis
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
These findings lend new insight to how changes in p85 gene dosage or mutations in p85 could lead to the hyper-activation of PI3K and thus contribute towards tumorigenesis.
|
16131837 |
2005 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Among them CBFA2T2, a member of the "ETO" family, is known because of its homology and association with the product of RUNX1-CBFA2T1 gene fusion generated by t(8;21) translocation, one frequent cause of acute myeloid leukemia.
|
20958258 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We determined which catalytic subunits of phosphoinositide 3-kinase (PI3K) were in active complex with the p85 regulatory subunit and showed enrichment for the α subunit in three CLLs carrying PIK3CA amplification.
|
22623730 |
2012 |
|
Polycythemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia.
|
19336760 |
2009 |
|
Juvenile Myelomonocytic Leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that the JMML-associated Cbl mutant in complex with the Src family kinase Lyn promotes Cbl's adapter function, leading to increased association to PI3K regulatory subunit p85 and Lyn-dependent AKT pro-survival signalling.
|
24469048 |
2015 |
|
Leukemogenesis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This is the first detection of a mutated form of the p85 subunit of PI3-kinase in human hematopoietic cells further underlining a potential role of PI3-kinase/Akt signaling in human leukemogenesis.
|
11986952 |
2002 |
|
Familial (FPAH)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia.
|
19336760 |
2009 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Using genetic models, we linked the PDE4-regulated modulation of P85 activation to the oncogenic kinase SYK.<b>Conclusions:</b> These data demonstrate that roflumilast and idelalisib suppress PI3K by distinct mechanisms, explaining the basis for their synergism, and suggest that the repurposing of PDE4 inhibitors to treat BCR-dependent malignancies is warranted.<i></i>.
|
29246942 |
2018 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In addition, the combination of P85 and (-)-gossypol effectively reduced clonogenic survival of A549 cells: (11 ± 5%) compared to (-)-gossypol and P85 alone (62 ± 27% and 93 ± 13%, respectively), and enhanced radiation cancer cell killing.
|
27827005 |
2017 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
|
16131837 |
2005 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Correction to: CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma.
|
29782581 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
|
16131837 |
2005 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
In addition, the combination of P85 and (-)-gossypol effectively reduced clonogenic survival of A549 cells: (11 ± 5%) compared to (-)-gossypol and P85 alone (62 ± 27% and 93 ± 13%, respectively), and enhanced radiation cancer cell killing.
|
27827005 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Correction to: CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma.
|
29782581 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In vivo, P85 (200 mg/kg/day) and (-)-gossypol (15 mg/kg/day) could be safely injected intravenously over 5 days and enhanced radiation-related tumor control in an A549 xenograft model.
|
27827005 |
2017 |